Vicore Pharma (VCRE) will participate in the Guggenheim healthcare conference on November 9 and the Stifel healthcare conference on November 12, 2026. CEO Ahmed Mousa will hold a fireside chat in Boston from 8:00–8:25 AM ET at Guggenheim and present in New York from 10:40–11:10 AM ET at Stifel. Both events include one-on-one meetings.

Vicore Pharma (VCRE): ASPIRE Phase 2b fully enrolled with 378 IPF patients, topline guided for mid-2027, SEK 905.6M liquidity at June 30, 2026.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Vicore Pharma (VCRE): ASPIRE Phase 2b fully enrolled with 378 IPF patients, topline guided for mid-2027, SEK 905.6M liquidity at June 30, 2026.

Vicore Pharma (VCRE): ASPIRE Phase 2b fully enrolled with 378 IPF patients, topline guided for mid-2027, SEK 905.6M liquidity at June 30, 2026.

Filed Oct 13. Who filed, the stake, and how it changed.

Schedule 13G filed Oct 13. Who filed, the stake, and how it changed.

Vicore Pharma (VCRE) will participate in the Chardan Healthcare Conference in New York on October 20, 2026. CEO Ahmed Mousa will join a panel on idiopathic pulmonary fibrosis and chronic respiratory disease from 2:00–2:30 PM ET. The event at the Lotte New York Palace will also include one-on-one meetings.

Reported Friday, Oct 9 - 4:58am EDT (TheFly subscription required to read more.)

Vicore Pharma (VCRE) increased its outstanding shares and votes by 118,916 following warrant exercises for participants in board incentive programs. The issuance followed the exercise of 117,737 share awards entitled to 118,916 shares under Board LTIP 2023, Board LTIP 2024 and Board RSU 2025.As of September 30, 2026, total registered shares and votes stood at 281,644,509. Share capital increased by 59,457.999424 SEK to a registered total of 140,822,253.132817 SEK.

What does the ASPIRE design say? Vicore Pharma published the design and baseline materials, which report no efficacy comparison between groups.

Vicore Pharma (VCRE) will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026, from 8:30 to 8:55 AM ET.The virtual event will feature a company presentation and 1×1 meetings with CEO Ahmed Mousa, CFO Hans Jeppsson and CMO Bernt van den Blink. Vicore focuses on angiotensin II type 2 receptor agonists, including its lead oral small molecule buloxibutid for idiopathic pulmonary fibrosis (IPF), which has Orphan Drug and Fast Track designations and is in a global 52‑week Phase 2b ASPIRE trial.

Vicore Pharma (NASDAQ:VCRE, STO:VICO) announced participation in two September 2026 healthcare conferences. At the Wells Fargo Healthcare Conference at Encore Boston Harbor in Boston, the company will hold 1×1 meetings on September 8 with CEO Ahmed Mousa. At the Cantor Global Healthcare Conference at the Waldorf Astoria New York, Mousa will join a fireside chat and 1×1 meetings on September 11 from 9:45–10:15 AM ET, which will be available via webcast.

Vicore Pharma (Nasdaq US:VCRE), a clinical-stage biopharmaceutical company focused on angiotensin II type 2 receptor agonists (ATRAGs), will present at the Pareto Securities 17th Annual Healthcare Conference at Hotel At Six in Stockholm.The company’s CFO, Hans Jeppsson, is scheduled to present on Wednesday, September 2, 2026, from 14:25 to 14:45 CEST. Vicore’s lead program, buloxibutid, an oral ATRAG for idiopathic pulmonary fibrosis, holds FDA Orphan Drug and Fast Track designations and is being studied in the 52-week Phase 2b ASPIRE trial.

Vicore Pharma (NASDAQ:VCRE, Nasdaq Stockholm:VICO) will present at the European Respiratory Society (ERS) Congress 2026, held September 5–9 in Barcelona and online. The company will share new data on the design and baseline characteristics of patients in its global 52-week Phase 2b ASPIRE trial of buloxibutid in idiopathic pulmonary fibrosis (IPF), and translational findings on angiotensin II type 2 receptor activation in alveolar epithelial type II cells and MMP-13.An oral presentation on ASPIRE-IPF is scheduled for September 7, 2026 at 11:35 CEST, and a poster on buloxibutid’s AT2 receptor activation and association with fibrosis resolution will be presented September 6, 2026 at 12:30 CEST. According to Vicore Pharma, ASPIRE completed enrollment in April 2026 with over 360 patients at more than 100 sites in 14 countries, enabling topline results in mid-2027. Presentation materials will be posted on the company’s website.

Detta händer fredag den 21 augusti : Börsen, Aktier & Ekonomi OMXprat: https://omxprat.forumotion.eu > Dagens rekar < Detta händer fredag den 21 augusti : Börs